Skip to main content
Clinical Trials/NCT00583258
NCT00583258
Withdrawn
Not Applicable

A Randomized, Double-Blinded Placebo-Controlled Trial of Alfuzosin (Xatral)in the Management of Distal Ureteral Calculi

Unity Health Toronto1 site in 1 countryOctober 2007

Overview

Phase
Not Applicable
Intervention
Alfuzosin (Xatral)
Conditions
Kidney Stones
Sponsor
Unity Health Toronto
Locations
1
Primary Endpoint
The primary outcome will be Cox proportional hazards survival analysis of stone passage over time
Status
Withdrawn
Last Updated
10 years ago

Overview

Brief Summary

Patients who present for the first time to Emergency Room with renal colic due to a distal ureteral calculus (as diagnosed with spiral CT scan and KUB) will be randomized to receive Xatral 10mg po once a day or placebo once discharged from the ER. The purpose of this study is to assess if patients treated with Xatral will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Registry
clinicaltrials.gov
Start Date
October 2007
End Date
October 2009
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • first presentation to ER with renal colic secondary to a distal ureteral stone diagnosed on spiral CT scan
  • stone radiopaque on KUB, distal to the sacro-iliac joint
  • patient suitable for discharge from ER
  • patient willing to return for follow-up on a weekly basis for maximum 4 visits

Exclusion Criteria

  • more than one ureteral calculi
  • radiolucent stones or cystine stones
  • prior ipsilateral calculus or ureteral surgery
  • congenital anomalies of the ureter
  • patients presents with an absolute indication for intervention
  • allergy or contraindication to NSAIDs (history of orthostatic hypotension, current systolic BP \<90 mmHg)
  • patient currently taking an alpha-blocker
  • hepatic insufficiency
  • pregnancy

Arms & Interventions

A

Intervention: Alfuzosin (Xatral)

B

Intervention: Placebo Alfuzosin

Outcomes

Primary Outcomes

The primary outcome will be Cox proportional hazards survival analysis of stone passage over time

Time Frame: 4 weeks

Secondary Outcomes

  • Secondary outcomes will be stone passage rates, pain scores, intervention rates, hospitalization rates and complication rates(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials